<DOC>
	<DOCNO>NCT00428948</DOCNO>
	<brief_summary>This study 's purpose evaluate long-term safety efficacy tolvaptan versus placebo patient ADPKD .</brief_summary>
	<brief_title>Tolvaptan Phase 3 Efficacy Safety Study ADPKD</brief_title>
	<detailed_description>The current study evaluate whether tolvaptan potentially beneficial , maintain adequate safety profile , reduce rate total renal volume increase , impact onset , severity progression important consequence ADPKD .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney , Autosomal Dominant</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>GFR estimate ≥60 mL/ min Diagnosis ADPKD rapidly progressive kidney growth ( total volume ≥750 cc ) Magnetic Resonance Imaging ( MRI ) randomization Legal adult age able give Informed Consent Willingness comply reproductive precaution female Prior exposure tolvaptan experimental PKD therapy Currently take medication purpose affect PKD cyst Women breast feeding female childbearing potential use acceptable contraceptive method In opinion study investigator sponsor may present safety risk confound study objectives Patients unlikely adequately comply study procedure Patients contraindication MRI Patients take medication illness likely affect ADPKD outcome .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>ADPKD</keyword>
	<keyword>Polycystic</keyword>
	<keyword>kidney</keyword>
	<keyword>ADPKD ( Autosomal Dominant Polycystic Kidney Disease )</keyword>
</DOC>